Related Experiment Videos
Cell-mediated immunity in epidermodysplasia verruciformis
Dermatologica
|January 1, 1976
Summary
Epidermodysplasia verruciformis impairs cell-mediated immunity (CMI), shown by reduced E rosettes and responses to PHA and Con A. This immune deficiency worsens with disease duration and lesion extent.
Area of Science:
- Immunology
- Dermatology
- Virology
Background:
- Epidermodysplasia verruciformis (EV) is a rare genetic disorder characterized by persistent human papillomavirus (HPV) infections and a high risk of skin cancer.
- Cell-mediated immunity (CMI) plays a crucial role in controlling viral infections and preventing tumor development.
Observation:
- Studies involved 6 EV patients and 2 healthy family members.
- Evaluated CMI using phytohemagglutinin (PHA), concanavalin A (Con A), lymphocyte rosette formation (E and EAC), bacterial skin tests, and dinitrochlorobenzene (DNCB) sensitization.
Findings:
- EV patients exhibited impaired CMI, evidenced by decreased E-rosette-forming lymphocytes and reduced responses to PHA and Con A.
- All EV patients showed negative immune responses to DNCB sensitization.
- CMI impairment correlated with disease duration and lesion extent, and was particularly severe in advanced tumor stages.
Implications:
- The findings highlight a significant CMI deficit in Epidermodysplasia Verruciformis.
- Understanding CMI impairment in EV is crucial for managing disease progression and cancer risk.
- Further research may explore immunotherapeutic strategies for EV patients.